LLY241122C990000
- 0.38
- 0.000.00%
Eli Lilly and Co Newsroom
Market Chatter: Eli Lilly, Novo Nordisk Press Employers to Cover the Cost of Weight-Loss Drugs
Eli Lilly's Muvalaplin Shows Positive Phase 2 Results in Reducing Heart Disease Risk Factor
Makers of Weight-Loss Drugs Want Your Employer to Pay for Them -- WSJ
Eli Lilly and Co (LLY.US) has a potential first-in-class oral small molecule that significantly reduces Lp(a) levels in adults at high risk of cardiovascular events.
Ruth Gimeno, Vice President of eli lilly and co Diabetes and Metabolism Research Group, said: "We are pleased to see these promising results and look forward to further exploring the next steps of muvalaplin's development."
Evercore Maintains Eli Lilly and Co(LLY.US) With Hold Rating
BMO Capital Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Cuts Target Price to $1,010
Weight-loss version of semaglutide launched in the Chinese market! novo-nordisk a/s (NVO.US) unlocks new growth engine.
novo-nordisk a/s launched Wegovy in china, with prices lower than in the usa; this is an important step for the company to intensify its investment in the rapidly growing market in china.
Top Gap Ups and Downs on Monday: TSLA, SMCI, LYFT and More
S&P Sees Some Signs of a US Credit Bubble as Spreads Tighten
Eli Lilly and Co Options Spot-On: On November 18th, 107.32K Contracts Were Traded, With 373.69K Open Interest
Monday Market Slow but Steady, Trump Buying Crypto Firm | Wall Street Today
Eli Lilly's Lipoprotein(a) Treatment Muvalaplin Meets Primary Endpoint in Trial
Express News | Lilly’s Muvalaplin Lowered Lipoprotein(a) Levels in Adults With High Risk for Cardiovascular Events by up to 85% at Highest Tested Dose
Trending Stocks Today | HCW Biologics Soars 442.8%
Sector Update: Health Care Stocks Mixed in Afternoon Trading
Eli Lilly on Track for Lowest Close Since February -- Data Talk
Top Midday Stories: Spirit Airlines Files for Chapter 11 Bankruptcy Protection; Trump Team Looking to Ease Rules for Self-Driving Cars
Monday Opens to S&P 500 Climb, Dow Slides as Eyes Look Toward Nvidia | Live Stock
Express News | Eli Lilly Shares Down 3.9%
Eli Lilly's Zepbound/Mounjaro Shows Cardiovascular Benefits In Patients With Obesity-Related Heart Failure